Illumina NovaSeq 6000 Sequencing System

Österreichische Akademie der Wissenschaften (ÖAW)

Wien | Website

Großgerät

Kurzbeschreibung

The Illumina NovaSeq 6000 provides ultrahigh-throughput sequencing for large sequencing projects. For genomic research it provides highest throughput and cost efficiency.

Ansprechperson

Christoph Bock

Research Services

The Biomedical Sequencing Facility (BSF) is an academic core facility and center of expertise for next generation sequencing (NGS) with more than 10 years experience in NGS.

The BSF offers advice and consulting for NGS experiments, NGS service (library preparation and sequencing) and bioinformatic data analysis to researchers and clinicians in Vienna, in Austria, and internationally.

The NGS protocols offered by the BSF include genome, transcriptome, epigenome and single-cell sequencing on short- and long-read sequencing platforms.

https://www.biomedical-sequencing.org/ngs-services/

Methoden & Expertise zur Forschungsinfrastruktur

The Biomedical Sequencing Facility (BSF) is Austria’s first technology platform dedicated to next generation sequencing in biomedicine and is thus expected to play a catalyzing role in the country’s development of genomic medicine.

The BSF not only operates next generation sequencing for Vienna’s medical campus (and beyond), but it also provides technological expertise and bioinformatic services for basic researchers and clinicians. Furthermore, it contributes to several flagship projects aimed at establishing proof-of-concept for genomic medicine in Austria.

https://biomedical-sequencing.at/BSF/

The Biomedical Sequencing Facility (BSF) is an academic core facility that serves researchers and clinicians in Vienna, in Austria, and internationally. The majority of projects involve the two partner institutions – the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna as well as the affiliated clinics, institutes, and laboratories. In addition, the BSF serves academic institutions in Austria and internationally as well as a small number of biotechnology and pharma companies, with an emphasis on protocols that are a special expertise of the BSF not widely available (including epigenome mapping and single-cell sequencing protocols).